ArticlePloS one2026
Challenges and opportunities in hydroxyurea access and adherence for sickle cell disease patients at Komfo Anokye Teaching Hospital: Insights from healthcare providers.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxyurea is a vital medication for managing Sickle cell disease, yet access and adherence remain significant challenges in low-resource settings. This qualitative study explored challenges and opportunities in hydroxyurea access and adherence among Sickle cell disease patients at the Komfo Anokye Teaching Hospital in Ghana. Alongside, the utility of the Ahodwo CommCare mobile App in enhancing Sickle cell disease management was explored. Semi-structured interviews were conducted with six healthcare providers, including doctors, nurses, and pharmacists from May 12 to August 15, 2022. This study found that the key barriers to hydroxyurea access and adherence include financial constraints, medication stock-outs, administrative inefficiencies, bureaucratic delays, patient-related factors such as forgetfulness and concerns about side effects, and practical challenges in administering the medication especially to children. The healthcare workers indicated that reconstituting the medication into suspension added both cost and time constraints to children who cannot take capsules hence affecting access to hydroxyurea. Facilitators to access and adherence identified included patient education, streamlined procurement processes, and government support for medication subsidies. This study found that patient education sessions should emphasize the benefits of hydroxyurea treatment and the importance of adherence to prescribed regimens. The study also revealed limited awareness and utilization of the Ahodwo CommCare app among healthcare personnel, highlighting the need for targeted training and integration into clinical workflows. These findings underscore the importance of multifaceted interventions involving healthcare workers, hospital management, and government stakeholders to improve hydroxyurea access and adherence, ultimately enhancing Sickle cell disease patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.